登录 | 注册    关注公众号  
搜索
 > 【LY75】

LY75信息

英文名称:Lymphocyte antigen 75
中文名称:淋巴细胞抗原-75
靶点别称:LY75,CD205,Lymphocyte Antigen 75,C-Type Lectin Domain Family 13 Member B,CLEC13B,DEC-205,CD205 Antigen,Gp200-MR6,Ly-75
上市药物数量:0
临床药物数量:2
最高研发阶段:临床一期

LY75产品列表

产品库
标签
属性
货号 物种 产品描述 蛋白结构 纯度 活性
LY5-H52H3
Human
Human LY75 / CD205 Protein, His Tag
LY5-M52H5
Mouse
Mouse LY75 / CD205 Protein, His Tag (MALS verified)
 
评论(1)
LY5-M52H5|Mouse LY75 / CD205 Protein, His Tag (MALS verified)
  1. 156XXXXXXX8
  2. 0人赞
  3. 小鼠的CD205蛋白纯度很高,我们采购小鼠的CD205蛋白,主要用于抗体的筛选。希望通过ELISA的方法,检测我们自主筛选获得的抗人CD205的抗体与小鼠的CD205间的交叉结合,希望能够筛选获得同时结合鼠和人CD205的抗体。
  4. 2022-04-06
 

LY75 分子别名

LY75,CD205,DEC-205,CLEC13B,Lymphocyte antigen 75,gp200-MR6

LY75 分子背景

lymphocyte antigen 75 (Ly 75, also known as CD205, CLEC13B, GP200-MR6 and DEC-205, is a type I transmembrane protein that is primarily expressed on dendritic cells and thymic epithelial cells. LY75 functions as an endocytic receptor for antigens. MEN1309/OBT076, the first antibody drug targeting CD205, has shown strong preclinical anti-tumor activity in lymphoma. After being verified as a single drug in vivo, the antibody-drug conjugate has a synergistic effect with the BCL2 inhibitor Venetoclax and the anti-cd20 monoclonal antibody rituximab.

LY75 前沿进展

LY75临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
MEN-1309 MEN-1309; OBT-076 临床一期 Oxford Biotherapeutics, Menarini 实体瘤, 非霍奇金淋巴瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定